Literature DB >> 14561085

Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.

Shantaram Kamath1, John K Buolamwini.   

Abstract

The overexpression and/or mutation of the epidermal growth factor receptor family of tyrosine kinases, namely EGFR and HER-2, have been implicated in poor prognosis of human solid tumors and are under investigation as molecular targets for cancer therapy. To gain insights into selectivity in the interaction of inhibitors at the ATP site of the two kinases, we have carried out docking, comparative molecular field analysis (CoMFA), and comparative molecular similarity analysis (CoMSIA) 3D-QSAR studies on 50 benzylidene malonitrile derivatives. Docking studies indicate different binding modes (A, B, C, D, and E) that are dependent on the R(1) substituent of the compounds. Binding modes A and B are favored by compounds having a hydroxyl substituent at R(1) whereas a methoxy substituent at R(1) results in compounds occupying binding modes, C, D, and E. The compounds preferred modes A, B, and C in the apo-enzyme whereas modes B, D, and E were preferred in the enzyme in complex with erlotinib. For 3D QSAR studies, based on the multiple binding modes obtained from the docking, four composite alignment strategies (I, II, III, IV) were employed and compared with alignment V, which is based on pairwise atom alignment of the common structural elements. Alignments I and II produced models with better predictive ability than those from alignments III and IV against an external test set. In the EGFR kinase results, alignments I and II produced comparable 3D-QSAR models with alignment II being slightly better than I, whereas in the HER-2 results, alignment I was better than alignment II in its predictive ability. It appears that differences in binding mode preferences at the ATP site might constitute a reason for the selectivity of the dihydroxy compounds as inhibitors of EGFR relative to HER-2. They are more likely to have multiple binding modes at the ATP site of EGFR, i.e., either modes A or B, than in the ATP site of HER-2 where they are possibly limited to only binding mode, A. Selectivity of the methoxy compounds on the other hand appears to depend on hydrogen bonding interactions involving the cyano group and residue 751 in the ATP site.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561085     DOI: 10.1021/jm030065n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.

Authors:  Cammy K-M Chen; Michael P Hudock; Yonghui Zhang; Rey-Ting Guo; Rong Cao; Joo Hwan No; Po-Huang Liang; Tzu-Ping Ko; Tao-Hsin Chang; Shiou-Chi Chang; Yongcheng Song; Jordan Axelson; Anup Kumar; Andrew H-J Wang; Eric Oldfield
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

2.  Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  Medchemcomm       Date:  2011-01-01       Impact factor: 3.597

3.  Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.

Authors:  Mayank Kumar Sharma; Prashant R Murumkar; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

4.  Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site.

Authors:  Shantaram A Kamath; John K Buolamwini
Journal:  J Comput Aided Mol Des       Date:  2005-05       Impact factor: 3.686

5.  A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2010-12

Review 6.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.

Authors:  Seetharama Satyanarayanajois; Stephanie Villalba; Liu Jianchao; Go Mei Lin
Journal:  Chem Biol Drug Des       Date:  2009-09       Impact factor: 2.817

8.  Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies.

Authors:  Saw Simeon; Nathjanan Jongkon; Warot Chotpatiwetchkul; M Paul Gleeson
Journal:  J Comput Aided Mol Des       Date:  2019-09-07       Impact factor: 3.686

9.  Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.

Authors:  Bing Yang; Yu-Shun Yang; Na Yang; Guigen Li; Hai-Liang Zhu
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

10.  3D QSAR studies, pharmacophore modeling, and virtual screening of diarylpyrazole-benzenesulfonamide derivatives as a template to obtain new inhibitors, using human carbonic anhydrase II as a model protein.

Authors:  Yeganeh Entezari Heravi; Hassan Sereshti; Ali Akbar Saboury; Jahan Ghasemi; Marzieh Amirmostofian; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.